Sugi Predict

Sugi Predict / Compounds / SCHEMBL6942213

SCHEMBL6942213

SCHEMBL6942213

CCc1cccc2cc(-c3nc([C@H]4CC[C@H](CNC(C)=O)CC4)n4ncnc(N)c34)[nH]c12

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MTOR P42345 4/20 0.59
▸ RICTOR Q6R327 3/20 0.59
▸ RPTOR Q8N122 3/20 0.59
▸ MAPKAP1 Q9BPZ7 3/20 0.59
▸ MLST8 Q9BVC4 3/20 0.59
▸ PIK3CA P42336 2/20 0.59
▸ PIK3CG P48736 2/20 0.59
▸ PRKDC P78527 2/20 0.59
▸ RIPK2 O43353 1/20 0.59
▸ RET P07949 1/20 0.59
▸ NQO2 P16083 1/20 0.59
▸ CSNK2A2 P19784 1/20 0.59
▸ FECH P22830 1/20 0.59
▸ ACVR1B P36896 1/20 0.59
▸ TGFBR1 P36897 1/20 0.59
▸ MAPK10 P53779 1/20 0.59
▸ MAP2K5 Q13163 1/20 0.59
▸ BMPR2 Q13873 1/20 0.59
▸ PIP4K2C Q8TBX8 1/20 0.59
▸ NLK Q9UBE8 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6941875 0.92 MTOR (0.60) MTORRICTORRPTORMAPKAP1MLST8
SCHEMBL6943868 0.91 MTOR (0.61) MTORRICTORRPTORMAPKAP1MLST8
SCHEMBL6943268 0.90 MTOR (0.65) MTORRICTORRPTORMAPKAP1MLST8
SCHEMBL6943400 0.89 MTOR (0.75) MTORRICTORRPTORMAPKAP1MLST8
SCHEMBL6943460 0.89 MTOR (0.57) MTORRICTORRPTORMAPKAP1MLST8
SCHEMBL6938946 0.88 RAF1 (0.74) MTORRICTORRPTORMAPKAP1MLST8
SCHEMBL11980643 0.88 IGF1R (0.57) MTORRICTORRPTORMAPKAP1MLST8
SCHEMBL6951464 0.88 MTOR (0.64) MTORRICTORRPTORMAPKAP1MLST8
SCHEMBL6943007 0.86 MTOR (0.78) MTORRICTORRPTORMAPKAP1MLST8
SCHEMBL6941922 0.85 MTOR (0.59) MTORRICTORRPTORMAPKAP1MLST8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8796455-B2 Fused bicyclic mTOR inhibitors OSI Pharmaceuticals, LLC (US) 2014-08-05 — — US disclosed
US-8796455-B2 Fused bicyclic mTOR inhibitors OSI Pharmaceuticals, LLC (US) 2014-08-05 — — US disclosed
US-8586546-B2 Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors OSI Pharmaceuticals, LLC (US) 2013-11-19 — — US disclosed
EP-2385053-B1 Intermediates for the preparation of fused bicyclic mTOR inhibitors OSI PHARM INC (US) 2013-10-02 — — EP disclosed
US-20130165651-A1 FUSED BICYCLIC mTOR INHIBITORS OSI Pharmaceuticals, LLC 2013-06-27 — — US disclosed
US-20130165651-A1 FUSED BICYCLIC mTOR INHIBITORS OSI Pharmaceuticals, LLC 2013-06-27 — — US disclosed
US-8314111-B2 Fused bicyclic motor inhibitors OSI Pharmaceuticals, LLC (US) 2012-11-20 — — US disclosed
US-8314111-B2 Fused bicyclic motor inhibitors OSI Pharmaceuticals, LLC (US) 2012-11-20 — — US disclosed
US-20120207767-A1 Combined Treatment with an EGFR Kinase Inhibitor and an Agent that Sensitizes Tumor Cells to the Effects of EGFR Kinase Inhibitors OSI PHARMACEUTICALS, LLC. 2012-08-16 — — US disclosed
US-20120207767-A1 Combined Treatment with an EGFR Kinase Inhibitor and an Agent that Sensitizes Tumor Cells to the Effects of EGFR Kinase Inhibitors OSI PHARMACEUTICALS, LLC. 2012-08-16 — — US disclosed
US-7651687-B2 Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2010-01-26 — — US disclosed
US-7651687-B2 Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2010-01-26 — — US disclosed
US-20090274698-A1 Combination anti-cancer therapy OSI PHARMACEUTICALS, INC. 2009-11-05 — — US disclosed
US-20090274698-A1 Combination anti-cancer therapy OSI PHARMACEUTICALS, INC. 2009-11-05 — — US disclosed
US-20090163468-A1 Fused Bicyclic mTor Inhibitors OSI PHARMACEUTICALS, INC. 2009-06-25 — — US disclosed
US-20090163468-A1 Fused Bicyclic mTor Inhibitors OSI PHARMACEUTICALS, INC. 2009-06-25 — — US disclosed
US-20070280928-A1 Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors OSI PHARMACEUTICALS, INC. 2007-12-06 — — US disclosed
US-20070280928-A1 Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors OSI PHARMACEUTICALS, INC. 2007-12-06 — — US disclosed
US-20070112005-A1 mammalian Target Of Rapamycin (mTOR) kinase; for treatment of lymphoma or ovarian cancer OSI PHARMACEUTICALS, INC. 2007-05-17 — — US disclosed
US-20070112005-A1 mammalian Target Of Rapamycin (mTOR) kinase; for treatment of lymphoma or ovarian cancer OSI PHARMACEUTICALS, INC. 2007-05-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163468-A1 Fused Bicyclic mTor Inhibitors MTOR, RICTOR, MAPKAP1 MTOR 1/4885RICTOR 2/4885RPTOR 4/4885
US-20120207767-A1 Combined Treatment with an EGFR Kinase Inhibitor and an Agent that Sensitizes Tumor Cells to the Effects of EGFR Kinase Inhibitors EGFR, ERBB2, MTOR MTOR 3/4885RICTOR 5/4885RPTOR 6/4885
US-20130165651-A1 FUSED BICYCLIC mTOR INHIBITORS MTOR, RICTOR, MAPKAP1 MTOR 1/4885RICTOR 2/4885RPTOR 4/4885
US-20090274698-A1 Combination anti-cancer therapy MTOR, RICTOR, AKT1 MTOR 1/4885RICTOR 2/4885RPTOR 7/4885
US-20070280928-A1 Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors EGFR, ERBB2, RICTOR MTOR 5/4885RICTOR 3/4885RPTOR 6/4885
US-20070112005-A1 mammalian Target Of Rapamycin (mTOR) kinase; for treatment of lymphoma or ovarian cancer MTOR, MAPKAP1, RPS6KA1 MTOR 1/4885RICTOR 6/4885RPTOR 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.